Back to Journals » Vascular Health and Risk Management » Volume 11

The role of factor Xa inhibitors in venous thromboembolism treatment

Authors Cabral K, Ansell J

Received 20 June 2014

Accepted for publication 17 July 2014

Published 30 January 2015 Volume 2015:11 Pages 117—123

DOI https://doi.org/10.2147/VHRM.S39726

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Katherine P Cabral,1 Jack E Ansell2

1Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2Hofstra-North Shore/LIJ School of Medicine, Hempstead, NY, USA

Abstract: Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism, both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban, apixaban, and edoxaban have all proven to be effective in Phase III clinical trials for this indication when compared to current standard of therapy with similar or less bleeding. Nevertheless, the agents all offer different pharmacological profiles, which have an impact on patient selection and potential advantages in clinical practice.

Keywords: anti-Xa inhibitors, apixaban, edoxaban, rivaroxaban, venous thromboembolism

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]